A phase 1b study of the combination of MLN0128 (dual TORC1/2 inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumors

被引：1
|
作者：
Davis, S. Lindsey [1 ]
Lam, Elaine T. [1 ]
Corr, Bradley R. [1 ]
O'Bryant, Cindy L. [1 ]
Glode, Ashley [1 ]
Adler, Nichole [1 ]
Pitts, Todd M. [1 ]
Tentler, John J. [1 ]
Capasso, Anna [1 ]
Dailey, Kyrie [1 ]
Serkova, Natalie J. [1 ]
Weekes, Colin D. [2 ]
Gustafson, Daniel L. [3 ]
Lieu, Christopher H. [1 ]
Messersmith, Wells A. [1 ]
Leong, Stephen [1 ]
Eckhardt, S. Gail [4 ]
Diamond, Jennifer R. [1 ]
机构：
[1] Univ Colorado, Denver, CO 80202 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Colorado State Univ, Ft Collins, CO 80523 USA
[4] Univ Texas Austin, Austin, TX 78712 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-A083
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A083
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase Ib study of the combination of MLN0128 (dual TORC1/2 inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumors, expansion cohort data
    Davis, S. L.
    Leong, S.
    Messersmith, W.
    Purcell, T.
    Lam, E.
    Corr, B.
    Leal, A.
    O'bryant, C.
    Glode, A.
    Adler, N.
    Serkova, N.
    Diamond, J.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E142 - E142
  • [2] A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in patients (pts) with advanced solid tumors.
    Olszanski, Anthony J.
    Middleton, Mark R.
    Bahleda, Rastilav
    Heist, Rebecca Suk
    Rangachari, Lakshmi
    Zhou, Xiaofei
    Bozon, Viviana
    Kneissl, Michelle
    Macarulla, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] A phase Ib study of the combination of alisertib (Aurora A kinase inhibitor) and MLN0128 (dual TORC1/2 Inhibitor) in patients with advanced solid tumors, final expansion cohort data.
    Davis, S. Lindsey
    Leal, Alexis Diane
    Messersmith, Wells A.
    Lieu, Christopher Hanyoung
    Lam, Elaine T.
    Corr, Bradley
    O'Bryant, Cindy L.
    Serkova, Natalie Julie
    Pitts, Todd
    Diamond, Jennifer Robinson
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors
    Shah, Hiral A.
    Fischer, James H.
    Venepalli, Neeta K.
    Danciu, Oana C.
    Christian, Sonia
    Russell, Meredith J.
    Liu, Li C.
    Zacny, James P.
    Dudek, Arkadiusz Z.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (05): : 413 - 420
  • [5] FOOD EFFECT STUDY OF THE INVESTIGATIONAL AURORA A KINASE (AAK) INHIBITOR MLN8237 (ALISERTIB) IN PATIENTS WITH ADVANCED SOLID TUMORS
    Falchook, G. S.
    Zhou, X.
    Rosen, L. S.
    Venkatakrishnan, K.
    Kurzrock, R.
    Mahalingam, D.
    Goldman, J.
    Jung, J.
    Milch, C.
    Sarantopoulos, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 168 - 168
  • [6] Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
    Falchook G.S.
    Zhou X.
    Venkatakrishnan K.
    Kurzrock R.
    Mahalingam D.
    Goldman J.W.
    Jung J.A.
    Ullmann C.D.
    Milch C.
    Rosen L.S.
    Sarantopoulos J.
    Drugs in R&D, 2016, 16 (1) : 45 - 52
  • [7] ABSORPTION, METABOLISM, AND EXCRETION OF ALISERTIB (MLN8237), AN AURORA A KINASE INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMAS
    Pusalkar, Sandeepraj
    Zhou, Xiaofei
    Li, Yuexian
    Cohen, Lawrence
    Liao, Mingxiang
    Yang, Johnny
    Chong, Saeho
    Venkatakrishnan, Karthik
    Chowdhury, Swapan
    DRUG METABOLISM REVIEWS, 2015, 47 : 195 - 195
  • [8] Open-Label, Multicenter, Phase 1 Study of Alisertib (MLN8237), an Aurora A Kinase Inhibitor, With Docetaxel in Patients With Solid Tumors
    Graff, Julie N.
    Higano, Celestia S.
    Hahn, Noah M.
    Taylor, Matthew H.
    Zhang, Bin
    Zhou, Xiaofei
    Venkatakrishnan, Karthik
    Leonard, E. Jane
    Sarantopoulos, John
    CANCER, 2016, 122 (16) : 2524 - 2533
  • [9] Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors
    Falchook, Gerald S.
    Venkatakrishnan, Karthik
    Sarantopoulos, John
    Kurzrock, Razelle
    Mita, Alain C.
    Fu, Siqing
    Mita, Monica M.
    Zhou, Xiaofei
    Jung, Jung Ah
    Ullmann, Claudio Dansky
    Milch, Catherine
    Rosen, Lee S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (07) : 563 - 572
  • [10] Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors
    Semrad, Thomas J.
    Kim, Edward J.
    Gong, I-Yeh
    Li, Tianhong
    Christensen, Scott
    Arora, Mili
    Riess, Jonathan W.
    Gandara, David R.
    Kelly, Karen
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (02) : 335 - 341
12345